Objective: Fibroblast growth factor 19 (FGF-19) and FGF-21 are novel metabolic regulators that improve insulin resistence and obesity in rodents. The objective of this study was to explore whether changes in serum concentrations of FGF-19 and FGF-21 contribute to positive metabolic effects of weight loss induced by surgical treatment of obesity sleeve gastrectomy (SG).
Methods: Serum concentrations of FGF-19 and 21, adiponectin, resistin, fatty acid binding protein-4 (FABP-4) and insulin were measured by commercial ELISA (BioVendor, CZ) and RIA kits (Cis Bio International, France) in 15 morbidly obese subjects before and 12 months after SG. The study was approved by the Ethical Committee of General University Hospital in Prague.
Results: SG markedly decreased body weight (122±7 vs 91±7 kg; P<0.01), body mass index, serum triglyceride, serum C-reactive protein and serum FABP-4 concentrations (54.5±5.9 vs 35.8±5.1 ng/ml; P<0.01) and significantly increased serum adiponectin and HDL concentrations. Serum insulin levels tended to decrease but the difference did not reach statistical significance. Serum resistin levels, blood glucose and glycated hemoglobin concentrations were not significantly affected by SG. Serum FGF-21 levels markedly decreased (214±42 vs 78±26 pg/ml; P<0.01) while serum FGF-19 levels significantly increased (119±21 vs 174±40 pg/ml; P<0.01) 12 months after SG. At baseline, serum FGF-19 positively correlated with serum resistin levels and was inversely related to serum insulin, leptin and free fatty acid levels. Serum FGF-21 positively correlated with serum FABP-4 and CRP concentrations and was inversely related to serum adiponectin levels. Neither baseline FGF-19 nor FGF-21 concentrations predicted the extent of weight loss induced by SG.
Conclusion: We conclude that weight loss induced by SG decreased serum FGF-21 and increased serum FGF-19 levels. The increase of FGF-19 after SG could contribute to some of positive metabolic effects accompanying weight loss.
Acknowledgement: Supported by MSM0021620814 and IGA NS10024-4.
Prague, Czech Republic
24 - 28 Apr 2010
European Society of Endocrinology